Biogen, EU and Eisai
We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The ...
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback